Publicly traded since June 2018, Xeris Pharmaceuticals (NASDAQ:XERS) is a specialty pharmaceutical company developing patient-friendly injectables for indications in diabetes, epilepsy, and immunology. With a novel technology platform that enables ready-to-use, room-temperature stable formulations of injectable and infusible therapies, the company is advancing a portfolio of solutions in various therapeutic categories, including its first commercial product, Gvoke®. Its proprietary XeriSol and XeriJect formulation technologies have the potential to offer distinct advantages over conventional product formulations, including eliminating the need for reconstitution, enabling long-term, room-temperature stability, significantly reducing injection volume, and eliminating the requirement for intravenous (IV) infusion. The company's disruptive formulation and delivery technologies allow for the subcutaneous delivery of highly concentrated, non-aqueous paste and liquid formulations of all drug classes, including small molecules, peptides, proteins, antibodies, and nucleic-acid-based therapeutics. he companys products include Xeris Glucagon, a glucagon rescue pen for severe hypoglycemia in type 1 and insulin-dependent type 2 diabetics; and Xeris G-Pen, a pre-loaded auto-injection pen with highly concentrated formulation. Its disruptive formulation-injection technologies allow the subcutaneous delivery of highly concentrated, paste, and liquid formulations of various drug classes, including small molecules, peptides, proteins, antibodies, and nucleotide-based therapeutics. Xeris Pharmaceuticals, Inc. also offers ready-to-use bio-pharmaceuticals delivered through injectable devices. Xeris (Nasdaq: XERS) is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world. With Xeris technology, new product formulations are designed to be easier to use by patients, caregivers, and health practitioners and help reduce costs for payers and the healthcare system.
